Day: September 20, 2024

Date: September 21, 2024 Location: Fort Worth Convention Center, Fort Worth, Texas NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) — Brag House, a premier platform for casual college gamers, announces the Lone Star Collegiate Clash: Esports and Scholars Expo 2024. This pivotal event, set for September 21, 2024, in partnership with the Fort Worth Sports Commission, will take place at the bustling Fort Worth Convention Center. The event is designed to encourage Texas colleges to foster more robust esports and gaming programs, aligning with the increasing interest and participation in esports across the state. This one-day expo will not only highlight competitive college gaming but also focus on recruitment and career opportunities within the esports industry. All current students, alumni from Texas colleges, and high school students exploring...

Innofactor Plc Managers’ Transactions, on September 20, 2024, at 16:55 Finnish time Innofactor Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirement Name: Anni Wahlroos Position: Other senior manager Issuer: Innofactor Oyj LEI: 7437008OSKQFEDZYD835 Notification type: INITIAL NOTIFICATION Reference number: 78136/5/4 ____________________________________________ Transaction date: 2024-09-19 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007637 Nature of transaction: DISPOSAL Transaction details (1): Volume: 32296 Unit price: 1.68 EUR Aggregated transactions (1): Volume: 32296 Volume weighted average price: 1.68 EUR Espoo, September 20, 2024 INNOFACTOR PLC Eija Theis, General Counsel Additional information: Eija Theis, General CounselInnofactor...

Inverse Relationship Between Gold and Bond YieldsBloomberg, U.S. Global InvestorsSan Antonio, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (“the Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors, today announces an update to the stock repurchase program, allowing for the orderly and systematic repurchase of up to $5 million worth of the Company’s common stock between September 13, 2024, and December 31, 2024. This represents 14% of the Company’s market capitalization. This strategic move, combined with the ongoing monthly dividend program, reinforces the Company’s dedication to delivering shareholder value through effective capital allocation and consistent returns. The Company’s Board of Directors (“the Board”) has...

Mullen’s commercial vehicles arrived in Dubai this weekMullen staff also on site in Dubai this week to meet with Volt leadership.First initial shipment included Class 1 and Class 3 EV vans and trucksVolt’s $210M order includes 300 vehicles this year and 3,000 vehicles in 2025.Mullen technical and sales team present in Dubai this week for delivery of first EV vehicles Mullen Automotive, working in conjunction with independent company, VoltiE Group, a Miami, Florida-based EV charging company, are collectively providing EV vehicles and charging equipment to Volt Mobility, a GCC-based vehicle transport and leasing company that offers both commercial electric and gas vehicles and EV charging throughout the Middle East BREA, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN)...

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering at a purchase price of $1.65 per share. In a concurrent private placement, the Company also agreed to issue to the same investors warrants to purchase up to 3,939,394 shares of common stock. The private placement warrants have an exercise price of $1.84 per...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen’s commitment to advancing medical innovations to treat people living with rare cholestatic liver diseasesPARIS, FRANCE, 20 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has conditionally approved Iqirvo® (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA...